Archive

Archive for the ‘ReNeuron Group (RENE.L)’ Category

ReNeuron (LSE: RENE.L) receives DSMB clearance to dose in ReN001 stem cell trial for stroke

September 1st, 2011 No comments

LSE: RENE.L’s independent Data Safety Monitoring Board (DSMB) for the clinical trial has recommended that the trial advance to the evaluation of a higher dose of ReN001. Read more…

Categories: ReNeuron Group (RENE.L)

ReNeuron (LSE:RENE.L) Update on Stroke Clinical Trial

March 9th, 2011 No comments

RENE.L updated the single dose progress in the PISCES clinical trial Read more…

Categories: P1 PISCES safety clinical trial, ReNeuron Group (RENE.L), Stem Cell Research

ReNeuron Group (RENE.L) settles Legal Dispute with Neuralstem (AMEX: CUR)

January 28th, 2011 No comments

RENE.L  it has reached a settlement with CUR regarding the existing litigation in the US between the parties. Read more…

Categories: AMEX: CUR, ReNeuron Group (RENE.L), Stem Cell Line Litigation, Stem Cell Research, Stem Cell Technology, Stem Line Litigation